Apollo Therapeutics

#Apollo Therapeutics #Financing #Fundraising #Investment

Apollo Therapeutics closes Series C financing at $260 million

Apollo Therapeutics has completed a second close of its Series C financing, raising an additional $33.5 million and bringing the total raised in this round by the company during 2023 to $260 million. Apollo is a UK-based biopharmaceutical company advancing a pipeline of therapeutic programmes in oncology, major inflammatory disorders… Read More

#Business & Investment #News

Business financing
#Apollo Therapeutics #Drug discovery #Funding

Apollo Therapeutics closes $226.5 million Series C financing 

Apollo Therapeutics, a biopharmaceutical company focused on translating fundamental medical research into medicines through a hub-and-spoke approach, has closed $226.5 million in a Series C financing, led by lead investor Patient Square Capital.  Financing significantly adds to the $195 million previously raised by the company, and to Apollo’s pipeline of… Read More

#Business & Investment #News